Testing picankibart for active psoriatic arthritis
Part of Bones, joints & muscles, Skin clinical trials.
This trial tests a new drug called picankibart to see if it helps people with active psoriatic arthritis who haven't gotten enough relief from standard treatments like NSAIDs or non-biologic DMARDs. It may be an option if you have at least 3 tender and 3 swollen joints and active or past plaque psoriasis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have had psoriatic arthritis for at least 3 months
- You have at least 3 tender joints and 3 swollen joints currently
- You have active plaque psoriasis (at least one patch 2 cm or larger), nail psoriasis, or a past history of plaque psoriasis
- You have tried NSAIDs or non-biologic DMARDs and they did not work well enough or caused side effects
- You have not used more than 2 biologic drugs before and are not on any prohibited medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medicine (HS-10374) for people with active psoriatic arthritis who have not responded well to standard treatments. It compares the drug to a placebo to see if it reduces joint pain, swelling, and skin symptoms.
This trial tests a new drug called tulisokibart for people with psoriatic arthritis (PsA), a condition that causes joint pain and skin plaques. It may help if you have not tried certain biologic medications or if they did not work well.
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
This trial compares two drugs, apremilast and adalimumab, to see which is more effective for people with psoriatic arthritis who have not responded well to methotrexate. It focuses on joint pain, swelling, and skin symptoms.
This study tests an oral medicine called zasocitinib for people with psoriatic arthritis who have not had enough relief from other treatments. It may help reduce joint pain and skin symptoms.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.